GT Biopharma Inc. Common Stock (GTBP) is a publicly traded Healthcare sector company. As of September 15, 2026, GTBP trades at $9.40 with a market cap of $15.54M and a P/E ratio of -1.70. GTBP moved -25.37% today. Year to date, GTBP is -40.75%; over the trailing twelve months it is -42.21%. Its 52-week range spans $4.91 to $96.25. Analyst consensus is moderatebuy with an average price target of $3.00. Rallies surfaces GTBP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for GTBP, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $9.40 |
| Market Cap | $15.54M |
| P/E Ratio | -1.70 |
| EPS | $-6.68 |
| Dividend Yield | 0.00% |
| 52-Week High | $96.25 |
| 52-Week Low | $4.91 |
| Volume | 213.29K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-28.35M |
| Gross Margin | 0.00% |
1 analysts cover GTBP: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is moderatebuy. Average price target: $3.00.